Trial Profile
A study of safety, tolerability and efficacy of Certican in de novo heart transplant (Tx) patients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Ciclosporin
- Indications Heart transplant rejection
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 27 Apr 2010 Actual end date (Jan 2007) added as reported by ClinicalTrials.gov.
- 29 Nov 2005 New trial record.